替吉奥隔日方案联合低剂量顺铂治疗老年非小细胞肺癌疗效观察

Observation of therapeutic efficacy of using S-1 every other day program and low dose DDP in the treatment of elderly patients with NSCLC

目的替吉奥胶囊施行隔日给药联合低剂量顺铂化疗,评价其对老年非小细胞肺癌(NSCLC)的疗效。方法将55例老年NSCLC患者分为两组,分别行替吉奥隔日给药联合低剂量顺铂治疗和常规剂量治疗,观察两组疗效和不良反应。结果隔日低剂量组和常规剂量组RR率分别为26.7%和28%,1、2年生存率分别为53.3%、33.3%和56%、32%,差异无统计学意义;但隔日低剂量组Ⅲ～Ⅳ级血液性、消化道等毒性反应明显低于常规剂量组。结论两方案近期疗效相同,但隔日低剂量组不良反应发生率低,不需水化,门诊随访治疗,实现低成本和良好患者依从性。

Objective The therapeutic efficacy of using S-1 every other day program plus low dose DDP and that of Conventional dose regimen to treat elderly patients with NSCLC were compared in this article. Methods All of 55 el- derly patents with NSCLC were divided into two groups, with one group being treated with the Gio every other day joint administration of low-dose cisplatin therapy and the other group with conventional-dose therapy for at least two cycles, during which the effects were observed and adverse reactions were performed pathological diagnosis. Results The next day, the RR rate of the low-dose group and the conventional-dose group were 26.7% and 28%, and the av- erage survival time for these two groups were respectively 53.3%, 33.3%, 56%, 32%. Therefore, the difference was not statistically significant; however, the next day the low-dose group was significantly lower than conventional dose group in Ⅲ～Ⅳ blood and gastrointestinal toxicity. Conclusion The efficacy of the two programs are the same. However, com- pared with the conventional--dose program, low-dose program has lower incidence of adverse effects, and does not need the hydration and outpatient follow-up treatment. It also has the advantages of low cost and good patient compliance.